Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals – ClinicalTrials.gov

Post author By EvidenceNotFear
Post date 30 April 2020

This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals.

Actual Study Start Date :	April 29, 2020
Estimated Primary Completion Date :	October 29, 2021
Estimated Study Completion Date :	April 6, 2023

https://clinicaltrials.gov/ct2/show/NCT04368728

Tags BioNTech, Clinical, ClinicalTrials.gov, COVID-19, Pharmaceutical Industry, Randomized Controlled Trials, Trials, Vaccination

Info This site is a curated archive of articles with a link to the source. Keywords and topics covered in the publication can be found above. Click on the tag to view a listing of similar articles.
Links Are any links broken? The page may have been taken down. Visit archive.is or archive.org to view the archive snapshot.
Links Help fight censorship and preserve information on the internet. Archive this source and links on archive.is and archive.org. Save a local copy on your own hard drive.